Investors News

Stipple Bio Secures New Funding

a16z is investing further in Stipple Bio, a biotech startup developing novel epitope-targeted cancer therapies to overcome current drug limitations.

StartupHub.ai Staff

By StartupHub.ai Staff, reviewed by Daniel Singer, Editor

1 min read

Stipple Bio Secures New Funding
Credit: a16z Blog

Venture capital firm a16z is doubling down on Stipple Bio, a biotech startup focused on a new frontier in oncology drug development. The investment underscores a growing trend in biotech startup funding, where precision is paramount.

Paul Ehrlich's century-old dream of "aiming chemically" to separate drug efficacy from collateral damage remains a core challenge in oncology drug development. While advancements like CAR-Ts and antibody-drug conjugates have improved tumor specificity, "on-target, off-tumor" toxicities still limit treatment effectiveness and patient tolerance.

Stipple Bio, co-founded by Aaron Ring and Aashish Manglik, seeks to address this by defining tumor specificity at the epitope level, not just RNA or protein expression. They are developing an "epitomics" platform, dubbed Pointillist, to discover unique pathological epitopes on cancer cells.

This platform aims to map tumor biology in unprecedented detail. It could pave the way for a new generation of epitope-targeted biologic therapies.

As Stipple Bio approaches clinical-stage status with its first lead drug candidate, the continued investment from a16z signals confidence in its approach to precision medicine.

Get the free daily brief every morning

Every morning the day's AI news, new AI startups and new funding rounds. Free and takes a few minutes to read, unsubscribe at any time.

Join 64,000 other subscribers.

TopicsStipple Bioa16zBiotechnologyCancer TherapyDrug DevelopmentPrecision MedicineEpitomics

StartupHub.ai Staff

Written by

StartupHub.ai Staff

Editorial team

The staff writers of StartupHub.ai, ranging from investment analysts to avid AI tool users, early adopters and critical enthusiasts. Backgrounds span engineering, business and the arts. We hold every piece to rigorous standards of research and review.

Daniel Singer

Written by

Daniel Singer

Editor, reviewed this article

Daniel Singer is an AI expert who has been writing about, covering and building AI technology since 2018.

Test your Agent Readiness now

Paste your website. How well ChatGPT, Claude and the other agents can read and use a site, in about a minute.

Watch

The videos behind the news, one flip at a time

The feed mixes the videos from our articles with startup demos and you flip through them like TV channels for free with no signup.